IMVT-1402 for adults with Graves' disease who remain overactive despite treatment
Tests IMVT-1402 in adults with Graves' disease still hyperthyroid on antithyroid medicine.
Key facts
- Who runs it
- Immunovant Sciences GmbH
- Where
- Auckland and Wellington, New ZealandSee the 2 sitesAlso in 18 other countries, 166 sites
- Trial code
- Registry title
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 210 people, planned
- Started
- 19 Jun 2025
- Expected to end
- May 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- IMVT-1402
- Placebo
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease whose thyroid is still overactive despite antithyroid drug (ATD) treatment.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Graves' disease with an overactive thyroid (hyperthyroid) despite antithyroid drug treatment.
- Earlier treatment
- Must have had antithyroid drug (ATD) treatment. People already successfully treated with radioactive iodine (RAI) or who had the whole thyroid removed cannot join.
Main reasons for not taking part
- Earlier successful radioactive iodine (RAI) therapy
- Surgery that removed the whole thyroid (total thyroidectomy)
- Another autoimmune disease needing treatment that the study doctor judges too risky
- Moderate-to-severe active thyroid eye disease needing urgent surgery, or planned surgery, radiation or medicine for it during the study
- Other exclusion reasons set in the protocol
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures
- Male or female participants aged ≥ 18 years
- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment
- Other, more specific inclusion criteria are defined in the protocol
Who cannot take part
- Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy
- Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk
- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation
- Additional exclusion criteria are defined in the protocol
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in New Zealand.
Also in 18 other countries, 166 sites
- AucklandHospital not named in the registryNo longer taking part
- WellingtonHospital not named in the registryTaking people
About the trial
What the trial wants to find out
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The 3 groups in the trial
- IMVT-1402 Dose 1Treatment being tested
Treatment: IMVT-1402
- IMVT-1402 Dose 2Treatment being tested
Treatment: IMVT-1402
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
- Plain-language title
- IMVT-1402 for adults with Graves' disease who remain overactive despite treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07018323, who can take part
- Record updated
- 30 October 2026